An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.
Primary Purpose
Acute Pain From Ankle Sprain or Strain
Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
K-103-IP
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Acute Pain From Ankle Sprain or Strain
Eligibility Criteria
Inclusion Criteria:
- Subject must provide informed consent before any study specific evaluation is performed.
- Subject is male or female aged 18 to 70 years, inclusive.
- Subject has a grade 1 (mild functional impairment) or grade 2 (moderate functional impairment) ankle strain or sprain that occurred within 48 hours before the Screening visit.
- Subject has pain intensity upon monopodal weight bearing of 5 to 8, inclusive, measured by an 11 point nominal rating scale (NRS), plus pain intensity score at rest that is less than upon monopodal weight bearing.
Exclusion Criteria:
- Subject has a grade 3 (severe functional impairment) strain or sprain, bilateral strain or sprain, or concomitant fracture or wound at the site of the strain or sprain.
- Subject has had an ankle strain or sprain to the same foot within 6 months before the Screening visit.
- Subject has received topical analgesic medication within 24 hours before the Screening visit.
- Subject has applied ice or compression to the injured area within 2 hours before the Screening visit.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo
K-103-IP
Arm Description
Placebo patch: 0% indomethacin
K-103-IP: 0.5% indomethacin
Outcomes
Primary Outcome Measures
Sum of Pain Intensity Difference(SPID) 0-72
Secondary Outcome Measures
Mean change from Baseline in pain intensity difference (PID)
Full Information
NCT ID
NCT02089425
First Posted
March 14, 2014
Last Updated
March 2, 2017
Sponsor
Kowa Research Institute, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02089425
Brief Title
An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Terminated
Why Stopped
Interim futility analysis
Study Start Date
April 2014 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kowa Research Institute, Inc.
4. Oversight
5. Study Description
Brief Summary
This is a randomized, double blind, placebo controlled, parallel group study to assess the efficacy and safety of K-103-IP compared with placebo patch for treatment of mild to moderate acute pain associated with ankle strain or sprain.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Pain From Ankle Sprain or Strain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
384 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo patch: 0% indomethacin
Arm Title
K-103-IP
Arm Type
Experimental
Arm Description
K-103-IP: 0.5% indomethacin
Intervention Type
Drug
Intervention Name(s)
K-103-IP
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo comparator
Primary Outcome Measure Information:
Title
Sum of Pain Intensity Difference(SPID) 0-72
Time Frame
72 Hours
Secondary Outcome Measure Information:
Title
Mean change from Baseline in pain intensity difference (PID)
Time Frame
168 Hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject must provide informed consent before any study specific evaluation is performed.
Subject is male or female aged 18 to 70 years, inclusive.
Subject has a grade 1 (mild functional impairment) or grade 2 (moderate functional impairment) ankle strain or sprain that occurred within 48 hours before the Screening visit.
Subject has pain intensity upon monopodal weight bearing of 5 to 8, inclusive, measured by an 11 point nominal rating scale (NRS), plus pain intensity score at rest that is less than upon monopodal weight bearing.
Exclusion Criteria:
Subject has a grade 3 (severe functional impairment) strain or sprain, bilateral strain or sprain, or concomitant fracture or wound at the site of the strain or sprain.
Subject has had an ankle strain or sprain to the same foot within 6 months before the Screening visit.
Subject has received topical analgesic medication within 24 hours before the Screening visit.
Subject has applied ice or compression to the injured area within 2 hours before the Screening visit.
Facility Information:
City
Birmingham
State/Province
Alabama
Country
United States
City
Phoenix
State/Province
Arizona
Country
United States
City
Tempe
State/Province
Arizona
Country
United States
City
Anaheim
State/Province
California
Country
United States
City
El Cajon
State/Province
California
Country
United States
City
Encinitas
State/Province
California
Country
United States
City
Los Angeles
State/Province
California
Country
United States
City
Ventura
State/Province
California
Country
United States
City
Boynton Beach
State/Province
Florida
Country
United States
City
Daytona Beach
State/Province
Florida
Country
United States
City
Doral
State/Province
Florida
Country
United States
City
Hialeah
State/Province
Florida
Country
United States
City
Jacksonville
State/Province
Florida
Country
United States
City
Kissimmee
State/Province
Florida
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
Oldsmar
State/Province
Florida
Country
United States
City
Orlando
State/Province
Florida
Country
United States
City
Port Orange
State/Province
Florida
Country
United States
City
Chicago
State/Province
Illinois
Country
United States
City
Overland Park
State/Province
Kansas
Country
United States
City
Owensboro
State/Province
Kentucky
Country
United States
City
Towson
State/Province
Maryland
Country
United States
City
Rochester
State/Province
Michigan
Country
United States
City
St. Louis
State/Province
Missouri
Country
United States
City
Great Falls
State/Province
Montana
Country
United States
City
Omaha
State/Province
Nebraska
Country
United States
City
Las Vegas
State/Province
Nevada
Country
United States
City
Atco
State/Province
New Jersey
Country
United States
City
New York
State/Province
New York
Country
United States
City
Charlotte
State/Province
North Carolina
Country
United States
City
Mooresville
State/Province
North Carolina
Country
United States
City
Morganton
State/Province
North Carolina
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Columbus
State/Province
Ohio
Country
United States
City
Dayton
State/Province
Ohio
Country
United States
City
Willoughby
State/Province
Ohio
Country
United States
City
Gresham
State/Province
Oregon
Country
United States
City
Rapid City
State/Province
South Dakota
Country
United States
City
Jackson
State/Province
Tennessee
Country
United States
City
Memphis
State/Province
Tennessee
Country
United States
City
Smyrna
State/Province
Tennessee
Country
United States
City
Austin
State/Province
Texas
Country
United States
City
Boerne
State/Province
Texas
Country
United States
City
El Paso
State/Province
Texas
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Bountiful
State/Province
Utah
Country
United States
City
Salt Lake City
State/Province
Utah
Country
United States
12. IPD Sharing Statement
Learn more about this trial
An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.
We'll reach out to this number within 24 hrs